Introduction: Sebaceous gland carcinoma (SGC) of the eyelid is an aggressive tumour with the ability to metastasise and an increased morbidity. Controversies regarding the epidemiology of this malignant eyelid tumour is widespread in the scientific literature. Western reports repeatedly describes eyelid SGC as a rare occurring tumour in general, accounting for 1%-3% of all eyelid tumours, however studies from Asia have uncovered a higher frequency of eyelid SGC including 54% of all eyelid tumours in Japan, and 43%-56% in India. We wish to retrieve observational data of eyelid SGC prevalence in proportion to total eyelid tumours, from pathological studies published worldwide to resolve this controversy.

Methods And Analysis: We will search Ovid Medline, EMBASE, Cochrane Central Register of Controlled Trials, Scopus and Google Scholar to identify published reports on eyelid SGC prevalence proportions, aiming to clarify the incidence of the tumour. We will include observational clinicopathological studies reporting prevalence with confirmed histopathology. No limitations on publication date or language will be applied. Data from the individual studies and study quality will be extracted by two individual reviewers. Study quality will be assessed using the JBI Critical Appraisal Instrument for Studies Reporting Prevalence Data. Raw proportions will be transformed and pooled using a random effects model for meta-analysis. And subgroup analysis according to geography will be performed. If data are deemed unsuitable for a meta-analysis, a narrative synthesis will be presented. We will judge the certainty of evidence and present whether this has an overall effect on the results. The results may shed light on a long-standing academic disparity of the scientific literature.

Ethics And Dissemination: This systematic review does not require ethical approval. The results of this proposed review will be the subject to a publication in an international peer-reviewed journal within the ophthalmic or pathological specialty.

Prospero Registration Number: CRD42023487141.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177665PMC
http://dx.doi.org/10.1136/bmjopen-2024-086213DOI Listing

Publication Analysis

Top Keywords

eyelid sgc
16
eyelid tumours
12
eyelid
10
will
10
sebaceous gland
8
gland carcinoma
8
systematic review
8
clinicopathological studies
8
sgc prevalence
8
studies reporting
8

Similar Publications

Molecular landscape of eyelid sebaceous gland carcinoma: A comprehensive review.

Indian J Ophthalmol

October 2024

Department of Ocular Pathology, Dr. Rajendra Prasad Centre for Ophthalmic Science, All India Institute of Medical Science, New Delhi, India.

Article Synopsis
  • Eyelid sebaceous gland carcinoma (SGC) is a tough type of skin cancer that can come back and spread to other parts of the body.
  • Researchers are studying the genes and changes inside the cells of this cancer to find better treatments for patients.
  • They discovered important genetic changes and pathways that help the cancer grow, which could lead to new targeted therapies and personalized medicine.
View Article and Find Full Text PDF

Clinicopathologic Features of Eyelid Sebaceous Gland Carcinoma Requiring Immunohistochemical Diagnosis.

Ocul Oncol Pathol

September 2024

Department of Ophthalmology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.

Article Synopsis
  • The study evaluated eyelid sebaceous gland carcinoma (SGC) by analyzing 27 patients diagnosed at Toyama University Hospital from 2016 to 2022, emphasizing the importance of immunohistochemistry for accurate diagnosis.!
  • Five patients misdiagnosed initially with other cancers (including squamous cell carcinoma) were correctly identified as having SGC through additional immunostaining for adipophilin and androgen receptor.!
  • The research highlights that SGC may be misdiagnosed as other malignancies, and that immunostaining is essential for a definitive diagnosis, particularly in cases of less differentiated cancers like SCC.!
View Article and Find Full Text PDF
Article Synopsis
  • Eyelid sebaceous gland carcinoma (SGC) is a serious cancer, typically treated through surgical excision, but this study looked at the impact of neoadjuvant chemotherapy (NACT) on treatment outcomes.
  • Over a 24-month period, 30 patients were evaluated, with 10 receiving NACT, which resulted in a 90% regression rate of tumors and some downstaging.
  • Despite significant tumor shrinkage, the perceived ease of surgery improved for only 40% of patients, indicating the need for adjustments in surgical approaches when using NACT.
View Article and Find Full Text PDF
Article Synopsis
  • This study analyzed 1302 cases of eyelid neoplasms over a decade in coastal China, focusing on tumor characteristics and potential influencing factors.
  • Out of the cases, 89.2% were benign and 10.8% were malignant, with intradermal nevus and basal cell carcinoma being the most common types.
  • Findings suggest that the occurrence of certain eyelid cancers varies by region, with higher incidences of basal cell carcinoma in areas with a better Sociodemographic Index and higher latitudes.
View Article and Find Full Text PDF

Eyelid/Periocular Sebaceous Gland Carcinoma in 500 Eyes: Analysis Based on 8th Edition American Joint Cancer Committee Classification.

Am J Ophthalmol

January 2025

The Operation Eyesight Universal Institute for Eye Cancer, LV Prasad Eye Institute (V.S.V., V.T., A.L., and S.K.), Hyderabad, Telangana, India. Electronic address:

Article Synopsis
  • The study looked at how different stages of a type of skin cancer called sebaceous gland carcinoma (SGC) affect patient outcomes.
  • They found that as the cancer stage increases (from Stage 0 to Stage IV), the chances of it spreading and causing serious health problems also go up.
  • The research shows that patients with later stages of SGC have a much higher risk of dying from the disease compared to those with early-stage cancer.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!